<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd"><html xml:lang="en" lang="en" xmlns="http://www.w3.org/1999/xhtml"><head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" /><meta name="ROBOTS" content="NOARCHIVE" /><meta name="googlebot" content="nosnippet" /><meta name="Document-Type" content="interaction" /><meta name="keywords" content="" /><title>Dopaminergics: British National Formulary</title><link type="text/css" rel="stylesheet" href="../../383/theme.css" /><link type="text/css" rel="stylesheet" href="204/style.css" /><link type="image/x-icon" rel="shortcut icon" href="../../favicon.ico" /><link rel="stylesheet" type="text/css" href="style/screen.css" media="screen" /><link rel="stylesheet" type="text/css" href="style/print.css" media="print" /><link rel="contents" type="text/html" href="index.htm" /><link rel="help" type="text/html" href="http://www.medicinescomplete.com/mc/help_page.htm" /><link rel="start" type="text/html" href="index.htm" title="British National Formulary" /><link rel="copyright" type="text/html" href="PHP0-publication-information.htm" title="Copyright information" /><link rel="bookmark" title="Skip Navigation" href="bnf_int554-dopaminergics.htm#pB" /><script type="text/javascript" src="https://ajax.googleapis.com/ajax/libs/jquery/1.8/jquery.min.js"></script><script type="text/javascript" src="../../383/scripts.js"></script><style type="text/css">
          .contentsbox { position: fixed; z-index:1001; }
          .contentsbox_wrap { overflow: hidden; width: 20px; height: 130px; position: absolute; left: 0; top: 0; }
        </style><!--[if IE 8]>
          <style type="text/css">
          #p1 {
          float: left;
          padding-bottom: 15em;
          }
          </style>
          <![endif]--><!--[if lte IE 8]>
          <style type="text/css">
          #start-search input {
          height: 28px;
          padding-top: 8px;
          }
          @media screen {
          #pV {
          display: block !important;
          }
          }
          </style>
          <![endif]--><!--[if IE 7]>
          <style type="text/css">
          #start-search input {
          position: absolute !important;
          left: 0;
          top: 0;
          }
          .as-shadow {
          margin-left: -4px !important;
          color: silver;
          }
          </style>
          <![endif]--><!--[if lte IE 7]>
          <style type="text/css">
          .menu {
          height: 1%;
          }
          .contentsbox {
          position: absolute;
          left: expression( ( 15 + ( ignoreMe2 = document.documentElement.scrollLeft ? document.documentElement.scrollLeft : document.body.scrollLeft ) ) + 'px' );
          top: expression( ( 250 + ( ignoreMe = document.documentElement.scrollTop ? document.documentElement.scrollTop : document.body.scrollTop) ) + 'px' );
          }
          .threecol_col3 {
          font-family: arial
          }
          .threecol_col3 a {
          font-family: verdana,helvetica,sans-serif
          }
          .threecol_col1 {
          font-family: arial
          }
          .threecol_col1 a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pE {
          font-family: arial
          }
          div#pE a {
          font-family: verdana,helvetica,sans-serif
          }
          div#pK {
          font-family: arial
          }
          div#pK a {
          font-family: verdana,helvetica,sans-serif
          }

          #account-info ul li a {
          width: 12em;
          }
          #opts ul li span {
          width: 12em;
          }
          div.as-select ul li ul li span {
          width: 40em;
          }
          div.menu ul li ul li {
          float: left !important;
          }
          #pQ fieldset, #qd, #input-box, #pub-list, #start-search, #end-search {
          display: inline;
          float: left;
          height: 100%;
          padding: 0;
          margin: 0;
          position: relative;
          }
          #hM a, #hM a img {
          border: none;
          display: inline-block;
          float: left;
          }
          #qd input {
          float: left;
          display: inline-block !important;
          }
          #start-search input {
          height: 28px;
          padding-top: 8px !important;
          }
          #end-search, #end-search input {
          height: 36px !important;
          }
          #hM, #content, #searchForm, #purple-menu {
          width: expression(document.body.clientWidth > 63 * parseInt(document.body.currentStyle.fontSize) ? '63em': 'auto');
          margin: 0 auto;
          }
          #pQ {
          z-index: 1;
          }
          </style>
          <![endif]--><!--[if lte IE 6]>
          <style type="text/css">
          body {
          height: 100%;
          }
          div.menu ul li a, div.menu ul li span {
          display: inline-block;
          }
          div.menu ul li ul li {
          clear: both;
          }
          div.as-select ul li span {
          height: 20px;
          padding-top: 16px;
          padding-left: 1em;
          padding-bottom: 0;
          padding-left: 1em;
          margin: 4px 0;
          border-right: 1px solid #888;
          background-image: url("images/dropdown_img.png");
          background-repeat: repeat-x;
          overflow-x: hidden;
          }
          div.as-select ul li ul li span {
          font: bold 10px Verdana !important;
          padding: 4px 1em !important;
          color: #2D2D2D;
          background: white;
          text-decoration: none !important;
          white-space: nowrap;
          border: none !important;
          float: left;
          }
          div.menu span.hover {
          background: #8F1F8D;
          color: white;
          }
          </style>
          <![endif]--></head><body><!--[if lte IE 6]>
          <script type="text/javascript">
          jQuery(document).ready(function($) {
          $('a.mclogo').html('<img src="images/mc_logo.gif" class="logo" />');
          });
          </script>
          <![endif]--><?highlighter off?><div id="hC"><div id="vH"><div id="pU"><a class="mclogo" href="http://www.medicinescomplete.com/about/"><img class="logo" src="../../images/mc_logo.png" alt="MedicinesComplete" /></a><div id="hM"><div id="vM" class="menu"><ul><li><a href="http://www.medicinescomplete.com/mc/index.htm">Home</a></li><li><a href="http://www.medicinescomplete.com/mc/help.htm">Help</a></li><li><a href="http://www.medicinescomplete.com/mc/feedback.htm?pub=bnf&amp;uri=bnf_int554-dopaminergics.htm">Feedback</a></li><li id="account-info"><a href="http://www.medicinescomplete.com/mc/account.htm">BNF.org Free Access</a><ul><li><a href="http://www.medicinescomplete.com/mc/account.htm">My Account</a></li><li><a href="http://www.medicinescomplete.com/mc/subscribe.htm">Subscribe</a></li><li><a href="http://www.medicinescomplete.com/mc/login.htm">Sign in different user</a></li><li><a href="http://www.medicinescomplete.com/mc/logout.htm">Sign out</a></li></ul></li></ul></div><a id="pD" accesskey="s" rel="bookmark" href="bnf_int554-dopaminergics.htm#pB" title="Skip Navigation">Skip Navigation</a></div></div><div id="pA"><div id="pG">Printed from: Joint Formulary Committee.  <i>British National Formulary</i>. [online] London: BMJ Group and Pharmaceutical Press.. &lt; http://www.medicinescomplete.com/ &gt; [Accessed on 13 Mar 2013 (GMT)].</div><div id="pQ"><form id="searchForm" method="get" action="http://www.medicinescomplete.com/mc/bnf/current/search.htm"><fieldset><legend>Details</legend><label for="search-in">Publication</label><label for="q">Search for</label><div id="qd"><div id="start-search"><div class="as-select menu" id="pub-list"><ul><li><span>British National Formulary</span><ul></ul></li></ul></div><div id="input-box"><input type="text" id="q" name="q" accesskey="4" /></div></div><div id="end-search"><input class="button" id="searchButton" type="submit" value="Search" name="searchButton" title="Search full text" /></div></div></fieldset></form><script type="text/javascript">$(document).ready(function(){$("#q").autoSuggest('http://www.medicinescomplete.com/mc/bnf/current/search/suggest.xml', {control: "#searchButton"});});</script></div></div></div></div><div id="pH"><div id="pN"><div id="pT"><!--[if lte IE 7]>
             
            <![endif]--><span class="cA"><a href="http://www.medicinescomplete.com/mc/">Home</a></span> &gt; <a href="index.htm">BNF March 2013</a> &gt; <a href="PHP8848-interactions.htm">Appendix 1 Interactions</a> &gt; <a href="PHP8852-list-of-drug-interactions.htm">List of drug interactions</a></div><div id="pP"><div class="threecol_col1">◄ <a accesskey="[" href="bnf_int553-domperidone.htm" title="Previous: Domperidone">Previous page</a></div><div class="threecol_col2"> </div><div class="threecol_col3"><a accesskey="]" href="bnf_int1066-rotigotine.htm" title="Next: Rotigotine">Next page</a> ►</div></div></div></div><div id="content"><div id="p1"><div id="pB"><?highlighter on?><h1>Dopaminergics</h1><?highlighter off?><?highlighter on?><div id="pC" class="jN"><p><strong>Dopaminergics</strong> has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int942-memantine.htm">Memantine</a></td><td><p><span>effects of </span><span>dopaminergics</span> <span>possibly enhanced by</span> <span>memantine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int611-methyldopa.htm">Methyldopa</a></td><td><p><span>antiparkinsonian effect of </span><span>dopaminergics</span> <span>antagonised by</span> <span>methyldopa</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Rotigotine</strong> belongs to <strong>Dopaminergics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>manufacturer of </span><span>rotigotine</span> <span>advises avoid concomitant use of</span> <span>antipsychotics</span> <span>(antagonism of effect)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int613-metoclopramide.htm">Metoclopramide</a></td><td><p><span>manufacturer of </span><span>rotigotine</span> <span>advises avoid concomitant use of</span> <span>metoclopramide</span> <span>(antagonism of effect)</span></p></td><td></td></tr></tbody></table><p><strong>Rasagiline</strong> belongs to <strong>Dopaminergics</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int232-antidepressants-ssri.htm">Antidepressants, SSRI</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>rasagiline</span> <span>given with</span> <span>SSRIs</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>rasagiline</span> <span>given with</span> <span>tricyclics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int195-ciprofloxacin.htm">Ciprofloxacin</a></td><td><p><span>plasma concentration of </span><span>rasagiline</span> <span>increased by</span> <span>ciprofloxacin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int882-dextromethorphan.htm">Dextromethorphan</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>rasagiline</span> <span>with</span> <span>dextromethorphan</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int854-entacapone.htm">Entacapone</a></td><td><p><span>plasma concentration of </span><span>rasagiline</span> <span>possibly reduced by</span> <span>entacapone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td class="cAI"><p><span>after stopping </span><span>rasagiline</span> <span>do not start</span> <span>fluoxetine</span> <span>for 2 weeks, also <span>rasagiline</span> should not be started until at least 5 weeks after stopping <span>fluoxetine</span></span></p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td class="cAI"><p><span>after stopping </span><span>rasagiline</span> <span>do not start</span> <span>fluvoxamine</span> <span>for 2 weeks</span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>risk of hypertensive crisis when </span><span>rasagiline</span> <span>given with</span> <span>MAOIs</span><span>, avoid <span>MAOIs</span> for at least 2 weeks after stopping <span>rasagiline</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int102-pethidine.htm">Pethidine</a></td><td class="cAI"><p><span>risk of CNS toxicity when </span><span>rasagiline</span> <span>given with</span> <span>pethidine</span> <span>(avoid <span>pethidine</span> for 2 weeks after <span>rasagiline</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int690-sympathomimetics.htm">Sympathomimetics</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>rasagiline</span> <span>with</span> <span>sympathomimetics</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Tolcapone</strong> belongs to <strong>Dopaminergics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td><p><span>avoid concomitant use of </span><span>tolcapone</span> <span>with</span> <span>MAOIs</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr></tbody></table><p><strong>Apomorphine</strong> belongs to <strong>Dopaminergics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>effects of </span><span>apomorphine</span> <span>antagonised by</span> <span>antipsychotics</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int854-entacapone.htm">Entacapone</a></td><td><p><span>effects of </span><span>apomorphine</span> <span>possibly enhanced by</span> <span>entacapone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1045-ondansetron.htm">Ondansetron</a></td><td class="cAI"><p><span>possible increased hypotensive effect when </span><span>apomorphine</span> <span>given with</span> <span>ondansetron</span><span>—avoid concomitant use</span></p></td><td></td></tr></tbody></table><p><strong>Selegiline</strong> belongs to <strong>Dopaminergics</strong> and has the following interaction information:</p><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int572-5ht-1-receptor-agonists.htm">5HT<sub>1</sub>-receptor Agonists</a></td><td><p><span>manufacturer of </span><span>selegiline</span> <span>advises avoid concomitant use with</span> <span>5HT<sub>1</sub> agonists</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td class="cAI"><p><span>CNS toxicity reported when </span><span>selegiline</span> <span>given with</span> <span>tricyclics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int233-citalopram.htm">Citalopram</a></td><td><p><span>manufacturer of </span><span>selegiline</span> <span>advises avoid concomitant use with</span> <span>citalopram</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int703-dopamine.htm">Dopamine</a></td><td class="cAI"><p><span>risk of hypertensive crisis when </span><span>selegiline</span> <span>given with</span> <span>dopamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int854-entacapone.htm">Entacapone</a></td><td><p><span>max. dose of 10mg </span><span>selegiline</span> <span>advised by manufacturer of</span> <span>entacapone</span> <span>if used concomitantly</span></p></td><td></td></tr><tr><td><a href="bnf_int964-escitalopram.htm">Escitalopram</a></td><td><p><span>manufacturer of </span><span>selegiline</span> <span>advises avoid concomitant use with</span> <span>escitalopram</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int234-fluoxetine.htm">Fluoxetine</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span><span>selegiline</span> <span>given with</span> <span>fluoxetine</span> <span>(<span>selegiline</span> should not be started until 5 weeks after stopping <span>fluoxetine</span>, avoid <span>fluoxetine</span> for 2 weeks after stopping <span>selegiline</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int235-fluvoxamine.htm">Fluvoxamine</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span><span>selegiline</span> <span>given with</span> <span>fluvoxamine</span> <span>(<span>selegiline</span> should not be started until 1 week after stopping <span>fluvoxamine</span>, avoid <span>fluvoxamine</span> for 2 weeks after stopping <span>selegiline</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int558-levodopa.htm">Levodopa</a></td><td><p><span></span> <span>selegiline</span> <span>enhances effects and increases toxicity of</span> <span>levodopa</span> <span>(reduce dose of <span>levodopa</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>enhanced hypotensive effect when </span><span>selegiline</span> <span>given with</span> <span>MAOIs</span><span>—manufacturer of <span>selegiline</span> advises avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int942-memantine.htm">Memantine</a></td><td><p><span>effects of </span><span>selegiline</span> <span>possibly enhanced by</span> <span>memantine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>selegiline</span> <span>with</span> <span>moclobemide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td class="cAI"><p><span>plasma concentration of </span><span>selegiline</span> <span>increased by</span> <span>oestrogens</span><span>—manufacturer of <span>selegiline</span> advises avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr><tr><td><a href="bnf_int85-opioid-analgesics.htm">Opioid Analgesics</a></td><td><p><span>manufacturer of </span><span>selegiline</span> <span>advises avoid concomitant use with</span> <span>opioid analgesics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int236-paroxetine.htm">Paroxetine</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span><span>selegiline</span> <span>given with</span> <span>paroxetine</span> <span>(<span>selegiline</span> should not be started until 2 weeks after stopping <span>paroxetine</span>, avoid <span>paroxetine</span> for 2 weeks after stopping <span>selegiline</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int102-pethidine.htm">Pethidine</a></td><td class="cAI"><p><span>hyperpyrexia and CNS toxicity reported when </span><span>selegiline</span> <span>given with</span> <span>pethidine</span> <span>(avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int664-progestogens.htm">Progestogens</a></td><td class="cAI"><p><span>plasma concentration of </span><span>selegiline</span> <span>increased by</span> <span>progestogens</span><span>—manufacturer of <span>selegiline</span> advises avoid concomitant use</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a>. For further information on interactions of oral progestogen-only contraceptives, see also <a href="PHP4944-oral-progestogen-only-contraceptives.htm#PHP4945">section 7.3.2.1</a>; parenteral progestogen-only contraceptives, see also <a href="PHP4960-parenteral-progestogen-only-contraceptives.htm#PHP4965">section 7.3.2.2</a>; the intra-uterine progestogen-only device, see also <a href="PHP4973-intra-uterine-progestogen-only-device.htm#PHP4974">section 7.3.2.3</a>; hormonal emergency contraception, see also <a href="PHP5019-hormonal-methods.htm#PHP5024">section 7.3.5</a></p></div></td></tr><tr><td><a href="bnf_int237-sertraline.htm">Sertraline</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span><span>selegiline</span> <span>given with</span> <span>sertraline</span> <span>(<span>selegiline</span> should not be started until 1 week after stopping <span>sertraline</span>, avoid <span>sertraline</span> for 2 weeks after stopping <span>selegiline</span>)</span></p></td><td></td></tr><tr><td><a href="bnf_int690-sympathomimetics.htm">Sympathomimetics</a></td><td><p><span>manufacturer of </span><span>selegiline</span> <span>advises avoid concomitant use with</span> <span>sympathomimetics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int240-venlafaxine.htm">Venlafaxine</a></td><td class="cAI"><p><span>increased risk of hypertension and CNS excitation when </span><span>selegiline</span> <span>given with</span> <span>venlafaxine</span> <span>(<span>selegiline</span> should not be started until 1 week after stopping <span>venlafaxine</span>, avoid <span>venlafaxine</span> for 2 weeks after stopping <span>selegiline</span>)</span></p></td><td></td></tr></tbody></table><p><strong>Pergolide</strong> belongs to <strong>Dopaminergics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>effects of </span><span>pergolide</span> <span>antagonised by</span> <span>antipsychotics</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int613-metoclopramide.htm">Metoclopramide</a></td><td><p><span>antiparkinsonian effect of </span><span>pergolide</span> <span>antagonised by</span> <span>metoclopramide</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Amantadine</strong> belongs to <strong>Dopaminergics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>increased risk of extrapyramidal side-effects when </span><span>amantadine</span> <span>given with</span> <span>antipsychotics</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td><p><span>increased risk of side-effects when </span><span>amantadine</span> <span>given with</span> <span>bupropion</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int942-memantine.htm">Memantine</a></td><td class="cAI"><p><span>increased risk of CNS toxicity when </span><span>amantadine</span> <span>given with</span> <span>memantine</span> <span>(manufacturer of <span>memantine</span> advises avoid concomitant use)</span></p></td><td></td></tr><tr><td><a href="bnf_int611-methyldopa.htm">Methyldopa</a></td><td><p><span>increased risk of extrapyramidal side-effects when </span><span>amantadine</span> <span>given with</span> <span>methyldopa</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int341-quinine.htm">Quinine</a></td><td><p><span>plasma concentration of </span><span>amantadine</span> <span>possibly increased by</span> <span>quinine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int733-tetrabenazine.htm">Tetrabenazine</a></td><td><p><span>increased risk of extrapyramidal side-effects when </span><span>amantadine</span> <span>given with</span> <span>tetrabenazine</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Bromocriptine</strong> belongs to <strong>Dopaminergics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int20-alcohol.htm">Alcohol</a></td><td><p><span>tolerance of </span><span>bromocriptine</span> <span>reduced by</span> <span>alcohol</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>hypoprolactinaemic and antiparkinsonian effects of </span><span>bromocriptine</span> <span>antagonised by</span> <span>antipsychotics</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int553-domperidone.htm">Domperidone</a></td><td><p><span>hypoprolactinaemic effect of </span><span>bromocriptine</span> <span>possibly antagonised by</span> <span>domperidone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>plasma concentration of </span><span>bromocriptine</span> <span>increased by</span> <span>erythromycin</span> <span>(increased risk of toxicity)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int717-isometheptene.htm">Isometheptene</a></td><td class="cAI"><p><span>risk of toxicity when </span><span>bromocriptine</span> <span>given with</span> <span>isometheptene</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int166-macrolides.htm">Macrolides</a></td><td><p><span>plasma concentration of </span><span>bromocriptine</span> <span>possibly increased by</span> <span>macrolides</span> <span>(increased risk of toxicity)</span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>See also</em> Telithromycin</p></div></td></tr><tr><td><a href="bnf_int613-metoclopramide.htm">Metoclopramide</a></td><td><p><span>hypoprolactinaemic effect of </span><span>bromocriptine</span> <span>antagonised by</span> <span>metoclopramide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int584-octreotide.htm">Octreotide</a></td><td><p><span>plasma concentration of </span><span>bromocriptine</span> <span>increased by</span> <span>octreotide</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Cabergoline</strong> belongs to <strong>Dopaminergics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>hypoprolactinaemic and antiparkinsonian effects of </span><span>cabergoline</span> <span>antagonised by</span> <span>antipsychotics</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int553-domperidone.htm">Domperidone</a></td><td><p><span>hypoprolactinaemic effect of </span><span>cabergoline</span> <span>possibly antagonised by</span> <span>domperidone</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int169-erythromycin.htm">Erythromycin</a></td><td><p><span>plasma concentration of </span><span>cabergoline</span> <span>increased by</span> <span>erythromycin</span> <span>(increased risk of toxicity)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions do not apply to small amounts of erythromycin used topically</p></div></td></tr><tr><td><a href="bnf_int166-macrolides.htm">Macrolides</a></td><td><p><span>plasma concentration of </span><span>cabergoline</span> <span>possibly increased by</span> <span>macrolides</span> <span>(increased risk of toxicity)</span></p></td><td><div class="cG"><p><strong>Note:</strong> <em>See also</em> Telithromycin</p></div></td></tr><tr><td><a href="bnf_int613-metoclopramide.htm">Metoclopramide</a></td><td><p><span>hypoprolactinaemic effect of </span><span>cabergoline</span> <span>antagonised by</span> <span>metoclopramide</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Entacapone</strong> belongs to <strong>Dopaminergics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int715-adrenaline-epinephrine.htm">Adrenaline (epinephrine)</a></td><td><p><span></span> <span>entacapone</span> <span>possibly enhances effects of</span> <span>adrenaline (epinephrine)</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int241-antidepressants-tricyclic.htm">Antidepressants, Tricyclic</a></td><td><p><span>manufacturer of </span><span>entacapone</span> <span>advises caution with</span> <span>tricyclics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int430-apomorphine.htm">Apomorphine</a></td><td><p><span></span> <span>entacapone</span> <span>possibly enhances effects of</span> <span>apomorphine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int702-dobutamine.htm">Dobutamine</a></td><td><p><span></span> <span>entacapone</span> <span>possibly enhances effects of</span> <span>dobutamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int703-dopamine.htm">Dopamine</a></td><td><p><span></span> <span>entacapone</span> <span>possibly enhances effects of</span> <span>dopamine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int587-iron.htm">Iron</a></td><td><p><span>absorption of </span><span>entacapone</span> <span>reduced by <em>oral</em></span> <span>iron</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>avoid concomitant use of </span><span>entacapone</span> <span>with non-selective</span> <span>MAOIs</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int611-methyldopa.htm">Methyldopa</a></td><td><p><span></span> <span>entacapone</span> <span>possibly enhances effects of</span> <span>methyldopa</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td><p><span>manufacturer of </span><span>entacapone</span> <span>advises caution with</span> <span>moclobemide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int711-noradrenaline-norepinephrine.htm">Noradrenaline (norepinephrine)</a></td><td><p><span></span> <span>entacapone</span> <span>possibly enhances effects of</span> <span>noradrenaline (norepinephrine)</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int1051-rasagiline.htm">Rasagiline</a></td><td><p><span></span> <span>entacapone</span> <span>possibly reduces plasma concentration of</span> <span>rasagiline</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Rasagiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td><p><span>manufacturer of  </span><span>entacapone</span> <span>advises max. dose of 10mg</span> <span>selegiline</span> <span>if used concomitantly</span></p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int240-venlafaxine.htm">Venlafaxine</a></td><td><p><span>manufacturer of </span><span>entacapone</span> <span>advises caution with</span> <span>venlafaxine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int222-warfarin.htm">Warfarin</a></td><td class="cAI"><p><span></span> <span>entacapone</span> <span>enhances anticoagulant effect of</span> <span>warfarin</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Levodopa</strong> belongs to <strong>Dopaminergics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int2-ace-inhibitors.htm">ACE Inhibitors</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>ACE inhibitors</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int15-adrenergic-neurone-blockers.htm">Adrenergic Neurone Blockers</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>adrenergic neurone blockers</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int26-alpha-blockers.htm">Alpha-blockers</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>alpha-blockers</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int809-amisulpride.htm">Amisulpride</a></td><td><p><span>avoidance of </span><span>levodopa</span> <span>advised by manufacturer of</span> <span>amisulpride</span> <span>(antagonism of effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int46-anaesthetics-general-volatile-liquids.htm">Anaesthetics, General (volatile liquids)</a></td><td class="cAI"><p><span>increased risk of arrhythmias when </span><span>levodopa</span> <span>given with</span> <span>volatile liquid general anaesthetics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int107-angiotensin-ii-receptor-antagonists.htm">Angiotensin-II Receptor Antagonists</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>angiotensin-II receptor antagonists</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int342-antimuscarinics.htm">Antimuscarinics</a></td><td><p><span>absorption of </span><span>levodopa</span> <span>possibly reduced by</span> <span>antimuscarinics</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Many drugs have antimuscarinic effects; concomitant use of two or more such drugs can increase side-effects such as dry mouth, urine retention, and constipation; concomitant use can also lead to confusion in the elderly. Interactions do not generally apply to antimuscarinics used by inhalation</p></div></td></tr><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>effects of </span><span>levodopa</span> <span>antagonised by</span> <span>antipsychotics</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int617-baclofen.htm">Baclofen</a></td><td><p><span>possible agitation, confusion and hallucinations when </span><span>levodopa</span> <span>given with</span> <span>baclofen</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int405-benzodiazepines.htm">Benzodiazepines</a></td><td><p><span>effects of </span><span>levodopa</span> <span>possibly antagonised by</span> <span>benzodiazepines</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int440-beta-blockers.htm">Beta-blockers</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>beta-blockers</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Since systemic absorption may follow topical application of beta-blockers to the eye the possibility of interactions, in particular, with drugs such as verapamil should be borne in mind</p></div></td></tr><tr><td><a href="bnf_int896-bupropion.htm">Bupropion</a></td><td><p><span>increased risk of side-effects when </span><span>levodopa</span> <span>given with</span> <span>bupropion</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int466-calcium-channel-blockers.htm">Calcium-channel Blockers</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>calcium-channel blockers</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int482-clonidine.htm">Clonidine</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>clonidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int522-diazoxide.htm">Diazoxide</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>diazoxide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int524-diuretics.htm">Diuretics</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>diuretics</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int763-hydralazine.htm">Hydralazine</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>hydralazine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int587-iron.htm">Iron</a></td><td><p><span>absorption of </span><span>levodopa</span> <span>possibly reduced by <em>oral</em></span> <span>iron</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int165-isoniazid.htm">Isoniazid</a></td><td><p><span>effects of </span><span>levodopa</span> <span>possibly reduced by</span> <span>isoniazid</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int257-maois.htm">MAOIs</a></td><td class="cAI"><p><span>risk of hypertensive crisis when </span><span>levodopa</span> <span>given with</span> <span>MAOIs</span><span>, avoid <span>levodopa</span> for at least 2 weeks after stopping <span>MAOIs</span></span></p></td><td><div class="cG"><p><strong>Note:</strong> For interactions of reversible MAO-A inhibitors (RIMAs) see Moclobemide, and for interactions of MAO-B inhibitors see Rasagiline and Selegiline; the antibacterial Linezolid is a reversible, non-selective MAO inhibitor</p></div></td></tr><tr><td><a href="bnf_int611-methyldopa.htm">Methyldopa</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>methyldopa</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int764-minoxidil.htm">Minoxidil</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>minoxidil</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int262-moclobemide.htm">Moclobemide</a></td><td><p><span>increased risk of side-effects when </span><span>levodopa</span> <span>given with</span> <span>moclobemide</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int615-moxonidine.htm">Moxonidine</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>moxonidine</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int631-nitrates.htm">Nitrates</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>nitrates</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int284-phenytoin.htm">Phenytoin</a></td><td><p><span>effects of </span><span>levodopa</span> <span>possibly reduced by</span> <span>phenytoin</span> <span></span></p></td><td></td></tr><tr><td><a href="bnf_int804-pyridoxine.htm">Pyridoxine</a></td><td><p><span>effects of </span><span>levodopa</span> <span>reduced by</span> <span>pyridoxine</span> <span>when given without dopa-decarboxylase inhibitor</span></p></td><td></td></tr><tr><td><a href="bnf_int687-selegiline.htm">Selegiline</a></td><td><p><span>enhanced effects and increased toxicity of </span><span>levodopa</span> <span>when given with </span><span>selegiline</span> <span>(reduce dose of <span>levodopa</span>)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Selegiline is a MAO-B inhibitor</p></div></td></tr><tr><td><a href="bnf_int765-sodium-nitroprusside.htm">Sodium Nitroprusside</a></td><td><p><span>enhanced hypotensive effect when </span><span>levodopa</span> <span>given with</span> <span>sodium nitroprusside</span> <span></span></p></td><td></td></tr></tbody></table><p><strong>Co-careldopa</strong> belongs to <strong>Dopaminergics</strong> but has no specific interaction information.</p><p><strong>Co-beneldopa</strong> belongs to <strong>Dopaminergics</strong> but has no specific interaction information.</p><p><strong>Pramipexole</strong> belongs to <strong>Dopaminergics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>manufacturer of </span><span>pramipexole</span> <span>advises avoid concomitant use of</span> <span>antipsychotics</span> <span>(antagonism of effect)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int744-cimetidine.htm">Cimetidine</a></td><td><p><span>excretion of </span><span>pramipexole</span> <span>reduced by</span> <span>cimetidine</span> <span>(increased plasma concentration)</span></p></td><td></td></tr></tbody></table><p><strong>Quinagolide</strong> belongs to <strong>Dopaminergics</strong> but has no specific interaction information.</p><p><strong>Ropinirole</strong> belongs to <strong>Dopaminergics</strong> and has the following interaction information:</p><table summary="Drug interactions" width="100%" border="0" cellspacing="2"><colgroup><col width="30%" class="cAG" /><col width="40%" class="cAF" /><col width="30%" class="cAH" /></colgroup><tbody><tr><td><a href="bnf_int363-antipsychotics.htm">Antipsychotics</a></td><td><p><span>manufacturer of </span><span>ropinirole</span> <span>advises avoid concomitant use of</span> <span>antipsychotics</span> <span>(antagonism of effect)</span></p></td><td><div class="cG"><p><strong>Note:</strong> Increased risk of toxicity with myelosuppressive drugs</p></div></td></tr><tr><td><a href="bnf_int195-ciprofloxacin.htm">Ciprofloxacin</a></td><td><p><span>metabolism of </span><span>ropinirole</span> <span>inhibited by</span> <span>ciprofloxacin</span> <span>(increased plasma concentration)</span></p></td><td></td></tr><tr><td><a href="bnf_int613-metoclopramide.htm">Metoclopramide</a></td><td><p><span>manufacturer of </span><span>ropinirole</span> <span>advises avoid concomitant use of</span> <span>metoclopramide</span> <span>(antagonism of effect)</span></p></td><td></td></tr><tr><td><a href="bnf_int636-oestrogens.htm">Oestrogens</a></td><td><p><span>plasma concentration of </span><span>ropinirole</span> <span>increased by</span> <span>oestrogens</span> <span></span></p></td><td><div class="cG"><p><strong>Note:</strong> Interactions of combined oral contraceptives may also apply to combined contraceptive patches and vaginal rings, see <a title="COCs interactions (target-block)" href="PHP4869-combined-hormonal-contraceptives.htm#PHP4875">section 7.3.1</a></p></div></td></tr></tbody></table></div><div id="pS"><p>Sub-sections</p><ul class="jT"><li><a href="bnf_int1066-rotigotine.htm" title="Rotigotine">Rotigotine</a></li><li><a href="bnf_int1051-rasagiline.htm" title="Rasagiline">Rasagiline</a></li><li><a href="bnf_int1042-tolcapone.htm" title="Tolcapone">Tolcapone</a></li><li><a href="bnf_int430-apomorphine.htm" title="Apomorphine">Apomorphine</a></li><li><a href="bnf_int687-selegiline.htm" title="Selegiline">Selegiline</a></li><li><a href="bnf_int659-pergolide.htm" title="Pergolide">Pergolide</a></li><li><a href="bnf_int555-amantadine.htm" title="Amantadine">Amantadine</a></li><li><a href="bnf_int556-bromocriptine.htm" title="Bromocriptine">Bromocriptine</a></li><li><a href="bnf_int557-cabergoline.htm" title="Cabergoline">Cabergoline</a></li><li><a href="bnf_int854-entacapone.htm" title="Entacapone">Entacapone</a></li><li id="_bnf_int558-levodopa"><a href="bnf_int558-levodopa.htm" title="Levodopa">Levodopa</a></li><li><a href="bnf_int881-pramipexole.htm" title="Pramipexole">Pramipexole</a></li><li><a href="bnf_int560-quinagolide.htm" title="Quinagolide">Quinagolide</a></li><li><a href="bnf_int686-ropinirole.htm" title="Ropinirole">Ropinirole</a></li></ul></div><?highlighter off?><div id="pE">◄ <a accesskey="[" href="bnf_int553-domperidone.htm">Previous: Domperidone</a> | <a class="top" href="bnf_int554-dopaminergics.htm#">Top</a> | <a accesskey="]" href="bnf_int1066-rotigotine.htm">Next: Rotigotine</a> ►</div></div></div></div><div id="pF"><div id="p2"><div id="pL"><div class="p4"><h2>Keep in touch</h2><ul><li><a href="http://www.pharmpress.com/?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Pharmaceutical Press</a></li><li><a href="http://www.rpharms.com/">Royal Pharmaceutical Society</a></li><li><a href="http://www.pharmpress.com/mc-alerts.asp?utm_source=medicinescomplete&amp;utm_medium=footer&amp;utm_campaign=medicinescomplete-referral">Sign up for our eNewsletter</a></li><li><a href="http://twitter.com/#!/PharmPress/" class="p5"><img src="../../images/twitter.png" alt="Twitter logo" />Follow us on Twitter
              </a></li><li><a href="http://www.facebook.com/pages/Pharmaceutical-Press/296104187066918" class="p5"><img src="../../images/facebook.png" alt="Facebook logo" />Find us on Facebook
              </a></li></ul></div><div class="p4"><h2>Help and Support</h2><ul><li><a accesskey="0" href="accessibility.htm" title="Accessibility information: access key 0">Accessibility</a></li><li><a href="http://www.medicinescomplete.com/about/contact.htm">Contact Us</a></li><li><a href="privacy.htm" title="Cookie and Privacy Policy">Cookie and Privacy Policy</a></li><li><a accesskey="3" href="http://www.medicinescomplete.com/mc/sitemap.htm" title="Site Map: access key 3">Site Map</a></li><li><a accesskey="8" href="terms.htm" title="Terms and Conditions: access key 8">Terms and Conditions</a></li></ul></div><div class="p4"><h2>Provided for</h2><div id="cL"><img src="../../images/mylogo.png" alt="BNF.org Free Access" id="pI" /></div></div><div id="pX"><p><a href="PHP0-publication-information.htm" rel="copyright">Copyright © BMJ Group and the Royal Pharmaceutical Society of Great Britain 2013.  All rights reserved.</a></p><p><a href="http://www.medicinescomplete.com/mc/copyright.htm">MedicinesComplete © The Pharmaceutical Press 2013</a></p></div></div></div></div><script type="text/javascript">$(document).ready(function(){$.ga('UA-9959526-1');});</script></body></html>